实用老年医学 ›› 2023, Vol. 37 ›› Issue (8): 865-872.doi: 10.3969/j.issn.1003-9198.2023.08.027
• 专家共识 • 上一篇
江苏省老年医学学会老年内分泌专业委员会, 江苏省医学会糖尿病学分会, 江苏省预防医学会糖尿病预防与控制专业委员会, 南京糖尿病并发症研究会老年分会
收稿日期:2023-03-05
出版日期:2023-08-20
发布日期:2023-08-28
通讯作者:
唐伟,Email: drtangwei@njmu.edu.cn;马向华,Email: 13952002505@139.com
Received:2023-03-05
Online:2023-08-20
Published:2023-08-28
中图分类号:
江苏省老年医学学会老年内分泌专业委员会, 江苏省医学会糖尿病学分会, 江苏省预防医学会糖尿病预防与控制专业委员会, 南京糖尿病并发症研究会老年分会. 老年2型糖尿病病人SGLT-2抑制剂应用专家共识[J]. 实用老年医学, 2023, 37(8): 865-872.
| [1] LI Y, TENG D, SHI X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369:m997. [2] LEROITH D, BIESSELS G J, BRAITHWAITE S S, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline[J]. J Clin Endocrinol Metab, 2019,104(5):15201574. [3] SELVIN E, CORESH J, BRANCATI F L. The burden and treatment of diabetes in elderly individuals in the U. S[J]. Diabetes Care, 2006, 29(11):24152419. [4] 《中国老年2 型糖尿病防治临床指南》编写组.中国老年2型糖尿病防治临床指南(2022年版)[J]. 中国糖尿病杂志, 2022, 30(1):2-51. [5] JI L, HU D, PAN C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients[J]. Am J Med, 2013, 126(10): 925.e11-925.e22. [6] 苏俊, 田慧, 李春霖, 等. 老年糖尿病住院患者死亡原因分析[J]. 第一军医大学学报, 2004, 24(1):110-112. [7] ZHENG L, LAN Q, ZHANG Y, et al. The screening value of baPWV and hs-crp to ASCVD in middle and elderly community population in Shanghai[J]. Int J Cardiol, 2015,186:289-290. [8] SCHIROS C G, DENNEY T S, GUPTA H. Interaction analysis of the new pooled cohort equations for 10-year atherosclerotic cardiovascular disease risk estimation: a simulation analysis[J]. BMJ Open, 2015, 5(4):e006468. [9] 郑亮, 吴宏, 钱定广, 等. 上海市高行老年社区人群动脉硬化性心血管疾病患病率的现况调查与危险因素分析[J]. 中国循证心血管医学杂志, 2016, 8(6): 680-682, 690. [10] D'ALESSANDRO C, PICCOLI G B, BARSOTTI M, et al. Prevalence and correlates of sarcopenia among elderly CKD outpatients on tertiary care[J]. Nutrients, 2018, 10(12): 1951. [11] KOOMAN J P, VAN DER SANDE F M, LEUNISSEN K M. Kidney disease and aging: a reciprocal relation[J]. Exp Gerontol, 2017, 87(Pt B):156-159. [12] LEE S J, SON H, SHIN S K. Influence of frailty on health-related quality of life in pre-dialysis patients with chronic kidney disease in Korea: a cross-sectional study[J]. Health Qual Life Outcomes, 2015, 13:70. [13] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409. [14] American Diabetes Association. Standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S135-S137. [15] USMAN M S, SIDDIQI T J, MEMON M M, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis[J]. Eur J Prev Cardiol, 2018, 25(5):495-502. [16] ZELNIKER T A, BRAUNWALD E. Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2020, 75(4):435-447. [17] MUSKIET M H A, WHEELER D C, HEERSPINK H J L. New pharmacological strategies for protecting kidney function in type 2 diabetes[J]. Lancet Diabetes Endocrinol, 2019, 7(5):397-412. [18] CINTRA R, MOURA F A, CARVALHO L S F, et al. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy[J]. Rev Assoc Med Bras(1992), 2019, 65(1):70-86. [19] CUSTÓDIO J S Jr, RORIZ-FILHO J, CAVALCANTI C A J, et al. Use of SGLT-2 inhibitors in older adults: scientific evidence and practical aspects[J]. Drugs Aging, 2020, 37(6):399-409. [20] LIN D S, LEE J K, CHEN W J. Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals[J]. J Clin Endocrinol Metab, 2021,106(7):2133-2145. [21] MILLER E M. Elements for success in managing type 2 diabetes with SGLT-2 inhibitors: individualizing treatment with SGLT-2 inhibitor therapy in type 2 diabetes mellitus[J]. J Fam Pract, 2017, 66(2 Suppl):S13-S16. [22] LU J, FU L, LI Y, et al. Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: a randomized, double blind, placebo controlled, phase 3 trial[J]. Diabetes Obes Metab, 2021, 23(5):1111-1120. [23] FERRANNINI E, RAMOS S J, SALSALI A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial[J]. Diabetes Care, 2010, 33(10):2217 -2224. [24] WENG J, ZENG L, ZHANG Y, et al. Henagliflozin as add on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: a multicentre, randomized, double blind, placebo controlled, phase 3 trial[J]. Diabetes Obes Metab, 2021, 23(8): 1754-1764.[25] STENLÖF K, CEFALU W T, KIM K A, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study[J]. Curr Med Res Opin, 2014, 30(2):163-175. [26] TSUSHIMA Y, LANSANG M C, MAKIN V. The role of SGLT-2 inhibitors in managing type 2 diabetes[J]. Cleve Clin J Med, 2021, 88(1):47-58. [27] GORING S, HAWKINS N, WYGANT G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis[J]. Diabetes Obes Metab, 2014, 16(5):433-442. [28] HÄRING H U, MERKER L, SEEWALDT-BECKER E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial[J]. Diabetes Care, 2014, 37(6):1650-1659. [29] ROSENSTOCK J, VICO M, WEI L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy[J]. Diabetes Care, 2012, 35(7):1473-1478. [30] CARRETERO GÓMEZ J, ARÉVALO LORIDO J C, GÓMEZ HUELGAS R, et al. Combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes: a real-world evidence study[J]. Can J Diabetes, 2019, 43(3):186-192. [31] 张洁, 郭立新.钠-葡萄糖共转运蛋白2抑制剂改善体重的特点、影响因素及其机制[J]. 中华糖尿病杂志, 2019, 11(4):287-290. [32] BODE B, STENLÖF K, HARRIS S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes[J]. Diabetes Obes Metab, 2015, 17(3):294-303. [33] LEITER L A, CEFALU W T, BRUIN T W, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension[J]. J Am Geriatr Soc, 2014, 62(7):1252-1262. [34] MATTHAEI S, BOWERING K, ROHWEDDER K, et al. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes[J]. Diabetes Obes Metab, 2015, 17(11):1075-1084. [35] NEAL B, PERKOVIC V, DE ZEEUW D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes[J]. Diabetes Care, 2015, 38(3):403-411. [36] MATTHAEI S, BOWERING K, ROHWEDDER K, et al. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial[J]. Diabetes Care, 2015, 38(3):365-372. [37] FULCHER G, MATTHEWS D R, PERKOVIC V, et al. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial[J]. Diabetes Ther, 2015, 6(3):289-302. [38] MEROVCI A, SOLIS-HERRERA C, DANIELE G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production[J]. J Clin Invest, 2014, 124(2):509-514. [39] LEE C G, BOYKO E J, BARRETT-CONNOR E, et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes[J]. Diabetes Care, 2011, 34(11):2381-2386. [40] BOLINDER J, LJUNGGREN Ö, JOHANSSON L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin[J]. Diabetes Obes Metab, 2014, 16(2):159-169. [41] ROSS S, THAMER C, CESCUTTI J, et al. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial[J]. Diabetes Obes Metab, 2015,17(7):699-702. [42] RODEN M, MERKER L, CHRISTIANSEN A V, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial[J]. Cardiovasc Diabetol, 2015, 14:154. [43] ZINMAN B, WANNER C, LACHIN J M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22):2117-2128. [44] BODE B, STENLÖF K, SULLIVAN D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial[J]. Hosp Pract(1995), 2013, 41(2):72-84. [45] CHILTON R, TIKKANEN I, CANNON C P, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2015, 17(12):1180-1193. [46] 田丽,王琼英,孙润民, 等. SGLT2i对2型糖尿病合并高血压患者24 h动态血压影响的荟萃分析[J]. 中华心血管病杂志, 2021, 49(10):1000-1011. [47] OELZE M, KRÖLLER-SCHÖN S, WELSCHOFP, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity[J]. PLoS One, 2014, 9(11):e112394. [48] AHMADIEH H, AZAR S. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus[J]. Diabetes Technol Ther, 2017, 19(9):507-512. [49] ZHAO Y, XU L, TIAN D, et al. Effects of sodium-glucose co-transporter 2(SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials[J]. Diabetes Obes Metab, 2018, 20(2):458-462. [50] HAO Z, HUANG X, SHAO H, et al. Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial[J]. Ther Clin Risk Manag, 2018, 14:2407-2413. [51] KANJI T, GANDHI M, CLASE C M, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis[J]. BMC Nephrol, 2015, 16:58. [52] NEAL B, PERKOVIC V, MAHAFFEY K W, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(7):644-657. [53] WIVIOTT S D, RAZ I, BONACA M P, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4):347-357. [54] CANNON C P, PRATLEY R, DAGOGO-JACK S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med, 2020, 383(15):1425-1435. [55] KANNEL W B, HJORTLAND M, CASTELLI W P. Role of diabetes in congestive heart failure: the Framingham study[J]. Am J Cardiol, 1974, 34(1):29-34. [56] 中国医师协会内分泌代谢科医师分会,《恒格列净临床应用专家指导意见》编写组. 恒格列净临床应用专家指导意见[J].中华糖尿病杂志, 2023,15(7):611-615.[57] PERKOVIC V, JARDINE M J, NEAL B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380(24):2295-2306. [58] HEERSPINK H J L, STEFÁNSSON B V, CORREA-ROTTER R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15):1436-1446. [59] BARNETT A H, MITHAL A, MANASSIE J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2014, 2(5):369-384. [60] TIKKANEN I, NARKO K, ZELLER C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension[J]. Diabetes Care, 2015, 38(3):420-428. [61] ROSENSTOCK J, FERRANNINI E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors[J]. Diabetes Care, 2015, 38(9):1638-1642. [62] HANDELSMAN Y, HENRY R R, BLOOMGARDEN Z T, et al. American association of clinical endocrinologists and American college of endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis[J]. Endocr Pract, 2016, 22(6):753-762. [63] YABE D,NISHIKINO R,KANEKO M,et al.Short-term impacts of sodium／glucose co-transporter2 inhibitors in Japanese clinical practice:considerations for their appropriate use to avoid serious adverse events[J].Expert Opin Drug Saf, 2015,14(6):795-800. [64] SUGIYAMA S, JINNOUCHI H, KURINAMI N, et al. Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes[J].J Atheroscler Thromb, 2018, 25(6):467-476. [65] RUANPENG D, UNGPRASERT P, SANGTIANJ, et al. Sodium-glucose cotransporter 2(SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis[J]. Diabetes Metab Res Rev, 2017, 33(6). doi: 10.1002/dmrr.2903. [66] TANG H L, LI D D, ZHANG J J, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2(SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials[J]. Diabetes Obes Metab, 2016, 18(12):1199-1206. [67] SCHWARTZ A V, JOHNSON K C, KAHN S E, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial[J]. J Bone Miner Res, 2012, 27(3):619-627. [68] RUSCICA M, BALDESSIN L, BOCCIA D, et al. Non-insulin anti-diabetic drugs: an update on pharmacological interactions[J]. Pharmacol Res, 2017, 115:14-24. [69] DEVINENI D, POLIDORI D.Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor[J]. Clin Pharmacokinet, 2015, 54(10):1027-1041. [70] MAY M, SCHINDLER C. Clinically and pharmacologically relevant interactions of antidiabetic drugs[J]. Ther Adv Endocrinol Metab, 2016, 7(2):69-83. [71] GU N, PARK S I, CHUNG H, et al. Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor[J]. Transl Clin Pharmacol, 2020, 28(1):17-33. [72] FEDIUK D J, NUCCI G, DAWRA V K, et al. Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2(SGLT2) inhibitor[J]. Clin Pharmacokinet, 2020, 59(8):949-965. [73] ZACCARDI F, WEBB D R, HTIKE Z Z, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis[J]. Diabetes Obes Metab, 2016,18(8):783-794. [74] DEVINENI D, VACCARO N, MURPHY J, et al. Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants[J]. Int J Clin Pharmacol Ther, 2015, 53(2):115-128. [75] DEVINENI D, MANITPISITKUL P, MURPHY J, et al. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants[J]. Clin Pharmacol Drug Dev, 2015, 4(4):279-286. [76] KASICHAYANULA S, LIU X, ZHANG W, et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin,a selective SGLT2 inhibitor,in healthy subjects[J]. Diabetes Obes Metab, 2011, 13(8) :770-773. [77] MACHA S, JUNGNIK A, HOHL K, et al. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2(SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers[J]. Int J Clin Pharmacol Ther, 2013, 51(11):873-879. [78] SAHASRABUDHE V, FEDIUK D J, MATSCHKE K, et al. Effect of food on the pharmacokinetics of ertugliflozin and its fixed-dose combinations ertugliflozin/sitagliptin and ertugliflozin/metformin[J]. Clin Pharmacol Drug Dev, 2019,8(5):619-627. |
| [1] | 王苏, 赵一璟, 魏晨敏, 陈堃, 曹雯, 王昆, 杨昱. 老年T2DM病人甘油三酯葡萄糖指数与低密度脂蛋白亚型的关系研究[J]. 实用老年医学, 2024, 38(10): 1002-1006. |
| [2] | 顾崇怀, 项学军, 郑元喜, 乔锐, 林松. 达格列净对接受冠状动脉介入治疗的伴有射血分数降低的心力衰竭合并2型糖尿病老年病人疗效观察[J]. 实用老年医学, 2024, 38(10): 1025-1029. |
| [3] | 周潇, 顾荣, 孔小岑, 罗勇, 王蔚萍, 马建华, 李惠琴. 桑枝总生物碱和卡格列净治疗血糖控制不佳的老年2型糖尿病病人的疗效观察[J]. 实用老年医学, 2024, 38(10): 1066-1069. |
| [4] | 刘倩慧, 姚子俊, 何玉立, 徐云凡, 吴军. 老年2型糖尿病合并慢性心力衰竭病人HbA1c水平对心脏结构和功能的影响[J]. 实用老年医学, 2024, 38(5): 491-437. |
| [5] | 刘童君, 赵雅洁, 胡洁玲, 胡洋, 梁伟. 糖代谢异常对血清激活素A水平的影响[J]. 实用老年医学, 2024, 38(5): 495-437. |
| [6] | 杨龙璇, 唐伟. 细胞衰老与2型糖尿病胰岛B细胞功能障碍的研究进展[J]. 实用老年医学, 2024, 38(5): 521-437. |
| [7] | 王金涛, 胡坚. 老年人2型糖尿病与肌少症的关系研究进展[J]. 实用老年医学, 2024, 38(5): 529-437. |
| [8] | 唐源, 邓暑芳, 何咏梅, 戴雨璇, 罗晶. 老年2型糖尿病病人健康素养水平及其与衰弱的相关性[J]. 实用老年医学, 2024, 38(3): 255-259. |
| [9] | 代玲俐, 俞匀. 老年2型糖尿病病人估计肾小球滤过率与胰岛素抵抗及胰岛B细胞功能的相关性研究[J]. 实用老年医学, 2023, 37(12): 1219-1223. |
| [10] | 范婷泳, 袁丽, 杨小玲, 陈茜. Caprini量表评估老年糖尿病病人静脉血栓栓塞症的效果[J]. 实用老年医学, 2023, 37(12): 1233-1237. |
| [11] | 张贺成, 魏苏. 老年2型糖尿病病人血清铁蛋白水平与糖尿病足发生的相关性[J]. 实用老年医学, 2023, 37(11): 1111-1114. |
| [12] | 胡艳, 巫海娣, 王雪菲, 娄青林, 叶青, 顾刘宝, 戴静, 宋小波. 老年2型糖尿病病人糖尿病足风险评分与尿微量白蛋白/肌酐的相关性分析[J]. 实用老年医学, 2023, 37(11): 1134-1137. |
| [13] | 宗前兴, 莫永珍. 老年2型糖尿病健康状态分层框架的应用与研究进展[J]. 实用老年医学, 2023, 37(11): 1170-1175. |
| [14] | 张林英, 梅群超, 张炜琦, 胡一兰. 抗阻训练联合高乳蛋白营养在老年2型糖尿病伴肌少症病人中的应用研究[J]. 实用老年医学, 2023, 37(10): 995-999. |
| [15] | 刘倩慧, 姚子俊, 何玉立, 吴军. SGLT2i对老年糖尿病病人心血管保护机制的研究进展[J]. 实用老年医学, 2023, 37(10): 1064-1068. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
|
